Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis

@article{Jendrek2016AntiGP2IA,
  title={Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis},
  author={Sebastian Torben Jendrek and Daniel Nils Gotthardt and Thomas Nitzsche and Laila Widmann and Tobias Korf and Maike Anna Michaels and Karl Heinz Weiss and Evaggelia Liaskou and Mette Vesterhus and Tom Hemming Karlsen and Swantje Mindorf and Peter Schemmer and F B{\"a}r and Bianca Teegen and Torsten Schr{\"o}der and Marc Ehlers and Christoph M. Hammers and Lars Komorowski and Hendrik Lehnert and Klaus Fellermann and Stefanie Derer and Johannes Roksund Hov and Christian Sina},
  journal={Gut},
  year={2016},
  volume={66},
  pages={137 - 144}
}
Objective Pancreatic autoantibodies (PABs), comprising antibodies against glycoprotein 2 (anti-GP2), are typically associated with complicated phenotypes in Crohn's disease, but have also been observed with variable frequencies in patients with UC. In a previous study, we observed a high frequency of primary sclerosing cholangitis (PSC) in patients with anti-GP2-positive UC. We therefore aimed to characterise the role of anti-GP2 in PSC. Design In an evaluation phase, sera from 138 well… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
42 Citations
Highly Influential Citations
1
Background Citations
13
Results Citations
2

42 Citations

Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?
TLDR
A potential biomarker, antiglycoprotein 2 (anti-GP2), is reported, in PSC, CCA, as well as secondary sclerosing cholangitis (SSC), which may identify the subgroup of patients with PSC at risk for CCA.
Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype
TLDR
Combined aGP21 and aGP24 IgA analysis is preferred to single aGP2 isoform analysis for sensitive PSC autoantibody testing and is associated with cirrhosis in PSC and could be used for risk stratification.
Serological biomarkers for management of primary sclerosing cholangitis
TLDR
Evidence on possible serological markers of PSC patients with particular clinical and genetic characteristics that could potentially help address the unmet clinical needs is reviewed.
The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia
TLDR
The report of an association between GP2 IgA autoAbs and disease severity in patients with PSC gave a new impetus to autoAb research for autoimmune liver diseases and might usher in a new era of serological research in this field.
The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood
TLDR
Differences in clinical and laboratory findings were observed in young patients, including higher incidence of overlap syndromes, mostly with autoimmune hepatitis, higher serum levels of aminotransferases and gamma-glutamyl transferase, and lower incidence of serious complications as cholangiocarcinoma.
Association between serum IgG level and clinical course in primary sclerosing cholangitis
TLDR
Elevated serum IgG levels at first diagnosis was identified as an independent risk factor for reduced transplant free-survival in patients with PSC and its influence on transplantation-free survival was studied.
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
TLDR
More attention should be paid to PSC patients presenting with an abrupt aggravation of jaundice, pain, fatigue, pruritus, weight loss, or worsening liver biochemistries, in particular within the first year after PSC diagnosis.
Cholangiocarcinoma in patients with primary sclerosing cholangitis.
TLDR
Despite ongoing advancements in the study of PSC-associated CCA, early diagnosis of CCA remains difficult, treatment options are limited, and prognosis is often consequently poor; Continued research in the development of high-accuracy diagnostic tools, novel biomarkers, and surveillance techniques may help to increase the likelihood of diagnosing CCA at earlier stages.
Autoantibodies in Autoimmune Liver Disease—Clinical and Diagnostic Relevance
TLDR
Practical aspects of antibody testing in the three major autoimmune liver diseases AIH, PBC, and PSC are reviewed, which suggest a link between disease pathogenesis and the intestinal microbiota.
Primary Sclerosing Cholangitis Overlapping with IBD
TLDR
Patients with PSC-IBD present a very high risk of developing colorectal neoplasia, usually located in the right colon, requiring routine endoscopic surveillance every year, starting from the moment PSC is diagnosed.
...
...

References

SHOWING 1-10 OF 35 REFERENCES
Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass.
TLDR
Determination of the ANCA titre and IgG subclass is unlikely to have a role in distinguishing between PSC + UC and UC only ANCA, and future identification of the antigen(s) for ANCA should allow the development of a more sensitive and specific test for the diagnosis of these two conditions.
Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease
TLDR
Determination of PABs and their subgroup analysis might identify patients with complicated disease behavior and were significantly more prevalent in patients with Crohn's disease than in ulcerative colitis.
Autoantibodies in primary sclerosing cholangitis.
TLDR
The present review aims to give an overview of the studies of autoantibodies in PSC, with a particular emphasis on the prevalence, clinical relevance and possible pathogenetic importance of each individual marker.
Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features.
Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
Anti‐neutrophil cytoplasmic antibody: A prognostic indicator in primary sclerosing cholangitis
TLDR
This study examines the presence of pANCA in patients with chronic liver disease, in particular those with PSC complicated by other biliary disease, and also patients who had undergone orthotopic liver transplantation.
Primary sclerosing cholangitis.
Glycoprotein 2 antibodies in Crohn's disease.
Immunopathogenesis of primary sclerosing cholangitis
TLDR
Associations with inflammatory bowel disease— especially ulcerative colitis— and with other auto-immune diseases, together with genetic associations, further suggest that PSC may be an immune-mediated disease.
Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis
TLDR
CA 19-9, body-weight and dominant bile duct stenosis are valuable indicators in detecting HBC in PSC patients, and a long history of IBD, male gender, and nicotine abuse are risk factors for the development of HBC.
...
...